Joaquim J Ferreira

Summary

Country: Portugal

Publications

  1. doi request reprint Skin cancer and Parkinson's disease
    Joaquim J Ferreira
    Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon, Portugal
    Mov Disord 25:139-48. 2010
  2. ncbi request reprint Sleep disruption, daytime somnolence and 'sleep attacks' in Parkinson's disease: a clinical survey in PD patients and age-matched healthy volunteers
    J J Ferreira
    Neurological Clinical Research Unit, Lisbon School of Medicine, Lisbon, Portugal
    Eur J Neurol 13:209-14. 2006
  3. ncbi request reprint Skin cancers and precancerous lesions in Parkinson's disease patients
    Joaquim Ferreira
    Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon, Portugal
    Mov Disord 22:1471-5. 2007
  4. ncbi request reprint The management of cervical dystonia
    Joaquim J Ferreira
    Neurological Clinical Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Centro de Estudos Egas Moniz, Faculdade de Medicina de Lisboa, 1649 028 Lisboa, Portugal
    Expert Opin Pharmacother 8:129-40. 2007
  5. ncbi request reprint [Botulinum toxin for the treatment of pain syndromes]
    Joaquim J Ferreira
    Unidade Neurológica de Investigação Clínica, Instituto de Medicina Molecular, Lisboa
    Acta Reumatol Port 31:49-62. 2006
  6. doi request reprint A double-blind, randomized, placebo and active-controlled study of nebicapone for the treatment of motor fluctuations in Parkinson's disease
    Joaquim J Ferreira
    Neurological Clinical Research Unit, Institute of Molecular Medicine, Lisbon, Portugal
    CNS Neurosci Ther 16:337-47. 2010
  7. doi request reprint What motivates Parkinson's disease patients to enter clinical trials?
    Anabela Valadas
    Department of Neurosciences, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisbon, Portugal
    Parkinsonism Relat Disord 17:667-71. 2011
  8. doi request reprint Late-stage Parkinson's disease: the Barcelona and Lisbon cohort
    Miguel Coelho
    Neurological Clinical Research Unit, Instituto de Medicina Molecular, Hospital Santa Maria, Lisbon, Portugal
    J Neurol 257:1524-32. 2010
  9. ncbi request reprint Prescribing patterns of antiparkinsonian agents in Europe
    Mario Miguel Rosa
    Laboratory of Clinical Pharmacology and Therapeutics, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon, Portugal
    Mov Disord 25:1053-60. 2010
  10. ncbi request reprint High prevalence of LRRK2 mutations in familial and sporadic Parkinson's disease in Portugal
    Joaquim J Ferreira
    Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon, Portugal
    Mov Disord 22:1194-201. 2007

Detail Information

Publications28

  1. doi request reprint Skin cancer and Parkinson's disease
    Joaquim J Ferreira
    Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon, Portugal
    Mov Disord 25:139-48. 2010
    ..Causal factors remain unknown. Due to the weak association between skin cancer and PD, no robust recommendation can be made regarding the need for periodic dermatological screening...
  2. ncbi request reprint Sleep disruption, daytime somnolence and 'sleep attacks' in Parkinson's disease: a clinical survey in PD patients and age-matched healthy volunteers
    J J Ferreira
    Neurological Clinical Research Unit, Lisbon School of Medicine, Lisbon, Portugal
    Eur J Neurol 13:209-14. 2006
    ..7%). Abnormal daytime somnolence and poor sleep quality at night are more frequent in PD patients than in normals. However, SA are reported in both groups, although less frequently in the normals during activities that requires attention...
  3. ncbi request reprint Skin cancers and precancerous lesions in Parkinson's disease patients
    Joaquim Ferreira
    Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon, Portugal
    Mov Disord 22:1471-5. 2007
    ..The frequency of actinic keratosis in PD patients and the associated risk to develop melanoma recommends its screening in future epidemiological studies...
  4. ncbi request reprint The management of cervical dystonia
    Joaquim J Ferreira
    Neurological Clinical Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Centro de Estudos Egas Moniz, Faculdade de Medicina de Lisboa, 1649 028 Lisboa, Portugal
    Expert Opin Pharmacother 8:129-40. 2007
    ....
  5. ncbi request reprint [Botulinum toxin for the treatment of pain syndromes]
    Joaquim J Ferreira
    Unidade Neurológica de Investigação Clínica, Instituto de Medicina Molecular, Lisboa
    Acta Reumatol Port 31:49-62. 2006
    ..This does not exclude the subsequent need to conduct pragmatic trials to evaluate the effectiveness of BoNT in conditions where the improvement of pain or any associated clinical sign or symptom may be of clinical relevance...
  6. doi request reprint A double-blind, randomized, placebo and active-controlled study of nebicapone for the treatment of motor fluctuations in Parkinson's disease
    Joaquim J Ferreira
    Neurological Clinical Research Unit, Institute of Molecular Medicine, Lisbon, Portugal
    CNS Neurosci Ther 16:337-47. 2010
    ..The results of this study show that nebicapone 150 mg is efficacious for the treatment of motor fluctuations in PD patients. However, the risk of increasing liver transaminases and its clinically relevance deserves further evaluation...
  7. doi request reprint What motivates Parkinson's disease patients to enter clinical trials?
    Anabela Valadas
    Department of Neurosciences, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisbon, Portugal
    Parkinsonism Relat Disord 17:667-71. 2011
    ..Limited data is available regarding motivations and concerns of Parkinson's disease (PD) patients when participating in clinical trials (CTs). Knowledge of these factors may improve the recruitment and quality of future trials...
  8. doi request reprint Late-stage Parkinson's disease: the Barcelona and Lisbon cohort
    Miguel Coelho
    Neurological Clinical Research Unit, Instituto de Medicina Molecular, Hospital Santa Maria, Lisbon, Portugal
    J Neurol 257:1524-32. 2010
    ..Motor and non-motor non-levodopa responsive problems were frequent and the main cause of disability. Fluctuations and dyskinesias were frequent though not disabling. Dementia is not unavoidable in these very late stages...
  9. ncbi request reprint Prescribing patterns of antiparkinsonian agents in Europe
    Mario Miguel Rosa
    Laboratory of Clinical Pharmacology and Therapeutics, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon, Portugal
    Mov Disord 25:1053-60. 2010
    ..Costs of medication increased more than did dose consume, implying an increase in the cost of individual patient treatment. Published evidence does not explain the observed differences in the prescribing of APA...
  10. ncbi request reprint High prevalence of LRRK2 mutations in familial and sporadic Parkinson's disease in Portugal
    Joaquim J Ferreira
    Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon, Portugal
    Mov Disord 22:1194-201. 2007
    ..These data have important implications for the diagnostic work-up and genetic counseling of patients with this disease in Portugal...
  11. doi request reprint Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease
    Joaquim J Ferreira
    Neurological Clinical Research Unit, Institute of Molecular Medicine, Lisbon, Portugal
    Clin Neuropharmacol 31:2-18. 2008
    ..To investigate the effects of nebicapone, a new catechol-O-methyltransferase (COMT) inhibitor, on levodopa pharmacokinetics, COMT activity, and motor fluctuations in Parkinson disease in comparison to placebo and entacapone...
  12. ncbi request reprint STN-DBS does not change emotion recognition in advanced Parkinson's disease
    Luisa Albuquerque
    Language Research Laboratory, University of Lisbon, and Department of Clinical Neurosciences, Santa Maria Hospital, Lisbon, Portugal Institute of Molecular Medicine and Faculty of Medicine, University of Lisbon, and Department of Clinical Neurosciences, Santa Maria Hospital, Lisbon, Portugal Electronic address
    Parkinsonism Relat Disord 20:166-9. 2014
    ....
  13. ncbi request reprint Clinical comparability of marketed formulations of botulinum toxin
    Cristina Sampaio
    Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine, Lisbon, Portugal
    Mov Disord 19:S129-36. 2004
    ....
  14. doi request reprint Botulinum toxin type-B improves sialorrhea and quality of life in bulbaronset amyotrophic lateral sclerosis
    Joao Costa
    Serviço de Neurologia Piso 7, Hospital de Santa Maria, Av Prof Egas Moniz, 1649 035 Lisboa
    J Neurol 255:545-50. 2008
    ..Sialorrhea is a disabling problem in bulbaronset amyotrophic lateral sclerosis (ALS). Botulinum toxin (BTX) type A and B have been proposed as alternatives to traditional treatments...
  15. doi request reprint Risk of drug-induced liver injury with the new oral anticoagulants: systematic review and meta-analysis
    Daniel Caldeira
    Clinical Pharmacology Unit, Instituto de Medicina Molecular, Lisbon, Portugal
    Heart 100:550-6. 2014
    ..The new oral anticoagulants (NOACs) have now reached the market. However, safety concerns have been raised about their hepatic safety. Therefore we aimed to evaluate NOAC liver-related safety...
  16. doi request reprint Caffeine does not increase the risk of atrial fibrillation: a systematic review and meta-analysis of observational studies
    Daniel Caldeira
    Laboratory of Clinical Pharmacology and Therapeutics, Faculty of Medicine, University of Lisbon, Lisboa, Portugal
    Heart 99:1383-9. 2013
    ..Atrial fibrillation (AF) is the most prevalent sustained arrhythmia, and risk factors are well established. Caffeine exposure has been associated with increased risk of AF, but heterogeneous data exist in the literature...
  17. pmc Survey of practices employed by neurologists for the definition and management of secondary non-response to botulinum toxin in cervical dystonia
    Joaquim J Ferreira
    Neurological Clinical Research Unit, Instituto de Medicina Molecular, Faculty of Medicine, University of Lisbon, Portugal
    Funct Neurol 27:225-30. 2012
    ..On the basis of our findings, SNR can be defined as insufficiently improved posture after ≥3 unsuccessful injection cycles in CD patients previously achieving satisfactory results...
  18. pmc Convergence of miRNA expression profiling, α-synuclein interacton and GWAS in Parkinson's disease
    Madalena Martins
    Neurological Clinical Research Unit, Instituto de Medicina Molecular, Lisboa, Portugal
    PLoS ONE 6:e25443. 2011
    ..A SNP in ST8SIA4 was also highly associated with PD (p = 6.15×10⁻³) in the meta-dataset. These findings suggest that several miRNAs may act as regulators of both known and novel biological processes leading to idiopathic PD...
  19. doi request reprint The placebo response in studies of acute migraine
    Ricardo Fernandes
    Pediatrics Department, Santa Maria Hospital, Lisbon, Portugal
    J Pediatr 152:527-33, 533.e1. 2008
    ..To characterize the magnitude of the placebo response in trials of migraine therapy in children and adolescents, and to identify its determinants...
  20. doi request reprint Branded versus generic clopidogrel in cardiovascular diseases: a systematic review
    Daniel Caldeira
    Laboratory of Clinical Pharmacology, Faculty of Medicine, University of Lisbon, Lisbon, Portugal
    J Cardiovasc Pharmacol 61:277-82. 2013
    ..The available evidence is therefore limited and does not support the existence of differences in efficacy or safety between branded and generic clopidogrel...
  21. doi request reprint Late-stage Parkinson disease
    Miguel Coelho
    Department of Neuroscience, Hospital Santa Maria, Neurological Clinical Research Unit, Instituto de Medicina Molecular, Lisbon, Portugal
    Nat Rev Neurol 8:435-42. 2012
    ..In this article, we review the changing landscape of the later stages of PD, and propose a definition of late-stage PD to designate patients who have progressed beyond the advanced stage...
  22. ncbi request reprint Evidence-based medicine (EBM) applied to Parkinson's disease treatment
    Cristina Sampaio
    Department of Pharmacology and Therapeutics, Lisbon School of Medicine, Hospital de Santa Maria, 1649 028 Lisbon, Portugal
    Parkinsonism Relat Disord 9:7-13. 2002
    ..The concept of management guidelines is presented along with commentaries to the potential variability of recommendations across the world. 3. Limitations of the clinical trials on Parkinson disease treatment so far available...
  23. doi request reprint Treatment options for non-motor symptoms in late-stage Parkinson's disease
    Miguel Coelho
    Neurological Clinical Research Unit, Institute of Molecular Medicine, Av Professor Egas Moniz, 1649 028, Lisbon, Portugal
    Expert Opin Pharmacother 9:523-35. 2008
    ..Few controlled clinical trials specifically addressed late-stage Parkinson's disease as a target population. There is a need for therapeutic data on the symptoms that most afflict late-stage Parkinson's disease patients...
  24. doi request reprint A randomized, rater-blinded, parallel trial of intensive speech therapy in sub-acute post-stroke aphasia: the SP-I-R-IT study
    Isabel Pavao Martins
    Language Research Laboratory, Department of Neurosciences, Lisbon Faculty of Medicine, Instituto de Medicina Molecular, Hospital de Sta Maria, Lisbon, Portugal
    Int J Lang Commun Disord 48:421-31. 2013
    ..There is conflicting evidence regarding the benefits of intensive speech and language therapy (SLT), particularly because intensity is often confounded with total SLT provided...
  25. pmc Pharmacotherapy in Parkinson's disease: case studies
    Tiago Mestre
    Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon, Portugal
    Ther Adv Neurol Disord 3:117-26. 2010
    ..The proposed therapeutic alternatives are discussed based on the best data available; that is, treatment guidelines, clinical trial results or observational data...
  26. ncbi request reprint Current and future therapeutic strategies for Parkinson's disease
    Tiago Fleming Outeiro
    Cell and Molecular Neuroscience Unit, Instituto de Medicina Molecular, Universidade de Lisboa, Av Prof Egas Moniz, 1649 028 Lisboa, Portugal
    Curr Pharm Des 15:3968-76. 2009
    ..The therapeutic potential of small molecule modulators of oligomer formation demands further exploration and validation in cellular and animal disease models in order to accelerate human drug development...
  27. pmc Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study
    Daniel G Healy
    Department of Clinical Neurosciences, Institute of Neurology, University College London, London, UK
    Lancet Neurol 7:583-90. 2008
    ..LRRK2-associated PD be distinguished from idiopathic PD; which mutations in LRRK2 are pathogenic; and what is the age-specific cumulative risk of PD for individuals who inherit or are at risk of inheriting a deleterious mutation in LRRK2?..
  28. ncbi request reprint Limitations of current Parkinson's disease therapy
    Olivier Rascol
    Clinical Investigation Centre and Department of Clinical Pharmacology, Toulouse, University Hospital France
    Ann Neurol 53:S3-12; discussion S12-5. 2003
    ..Therefore, the current antiparkinsonian therapy cannot be considered as ideal with regard to both efficacy and safety...